Home Multimedia Podcasts Subvisible Particles in Biotech Drugs Subvisible Particles in Biotech Drugs August 23, 2011 E. Morrey Atkinson, Ph.D., CSO, VP of R&D, Cook Pharmica /wp-content/uploads/2018/09/gencast_082211.mp3 PodcastsResourcesDrug research and developmentPharmacology Also of Interest StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline Seaport Therapeutics Launches with $100M Series A Blocking Mechanical Squeeze In Asthma Prevents Inflammatory Cycle StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers Related Media Emerging Markets Collaborate to Succeed in Post-Pandemic World Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development Moving the Drug Pipeline Forward with Mechanistic Modeling Related Content StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline Seaport Therapeutics Launches with $100M Series A Blocking Mechanical Squeeze In Asthma Prevents Inflammatory Cycle